Article Details

Takeda-backed Ambys tops out series A with $47M more to test liver cell therapy in 2023 ...

Retrieved on: 2021-12-21 17:58:12

Tags for this article:

Click the tags to see associated articles and topics

Takeda-backed Ambys tops out series A with $47M more to test liver cell therapy in 2023 .... View article details on hiswai:

Excerpt

Takeda participated in the funding round, which was led by Third Rock Ventures and included backing from Schroders Capital, Laurion Capital, ...

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up